# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000200406-26-000087
Filing Date
2026-04-22
Accepted
2026-04-22 16:02:41
Documents
85
Period of Report
2026-03-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | jnj-20260329.htm iXBRL | 10-Q | 1932046
2 | EX-31.1 CEO | a20261qex311ceocertificati.htm | EX-31.1 | 8447
3 | EX-31.2 CFO | a20261qex312cfocertificati.htm | EX-31.2 | 8407
4 | EX-32.1 CEO | a20261qex321ceocertificati.htm | EX-32.1 | 4697
5 | EX-32.2 CFO | a20261qex322cfocertificati.htm | EX-32.2 | 4576
11 |  | jnj-20260329_g1.jpg | GRAPHIC | 24354
12 |  | jnj-20260329_g2.jpg | GRAPHIC | 32390
13 |  | jnj-20260329_g3.jpg | GRAPHIC | 24284
14 |  | jnj-20260329_g4.jpg | GRAPHIC | 13956
15 |  | jnj-20260329_g5.jpg | GRAPHIC | 15118
16 |  | jnj-20260329_g6.jpg | GRAPHIC | 17316
17 |  | jnj-20260329_g7.jpg | GRAPHIC | 17764
| Complete submission text file | 0000200406-26-000087.txt |  | 11557889

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | jnj-20260329.xsd | EX-101.SCH | 66674
7 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | jnj-20260329_cal.xml | EX-101.CAL | 86671
8 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | jnj-20260329_def.xml | EX-101.DEF | 351125
9 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | jnj-20260329_lab.xml | EX-101.LAB | 815607
10 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | jnj-20260329_pre.xml | EX-101.PRE | 567410
89 | EXTRACTED XBRL INSTANCE DOCUMENT | jnj-20260329_htm.xml | XML | 2284435

Mailing Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK NJ 08933
Business Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK NJ 08933 732-524-2455
JOHNSON & JOHNSON (Filer) CIK: 0000200406 (see all company filings)

EIN.: 221024240 | State of Incorp.: NJ | Fiscal Year End: 0103
Type: 10-Q | Act: 34 | File No.: 001-03215 | Film No.: 26883662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)